US Pharma MarketingThe post GE HealthCare agrees to acquire SOFIE Biosciences in $945m deal appeared first on Medical Device Network.
GE HealthCare agrees to acquire SOFIE Biosciences in $945m deal
The cash deal to acquire the PET radiopharmaceuticals CMO from Trilantic North America is expected to close in H1 2027. The cash deal to acquire the PET radiopharmaceuticals CMO from Trilantic North America is expected to close in H1 2027. Under the deal, GE HealthCare will inherit SOFIE Biosciences’ US network of 15 CMO sites and its theranostics-focused contract development and manufacturing organisation (CDMO) site. Credit: Anne Czichos/Shutterstock.com GE HealthCare has agreed to acquire SOFIE Biosciences, a contract manufacturing organisation (CMO) specialising in positron emission tomography (PET) radiopharmaceuticals, from Trilantic North America in a $945m deal. Under the all-cash transaction,…
The cash deal to acquire the PET radiopharmaceuticals CMO from Trilantic North America is expected to close in H1 2027.
Source: Medical Device Network